Literature DB >> 27201706

Evaluation of Use of Belimumab In Clinical Practice Settings (Observe Study) In Spain: Health Resource Utilization and Labour Absenteeism.

J Cortés1, J L Andreu2, J Calvo3, A M García-Aparicio4, C G Coronell5, S Díaz-Cerezo5.   

Abstract

Year:  2014        PMID： 27201706     DOI： 10.1016/j.jval.2014.08.1703

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  8 in total

1.  Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.

Authors:  Ioannis Parodis; Alvaro Gomez; Julius Lindblom; Jun Weng Chow; Andrea Doria; Mariele Gatto
Journal:  Front Med (Lausanne)       Date:  2022-04-28

Review 2.  Belimumab: A Review in Systemic Lupus Erythematosus.

Authors:  Hannah A Blair; Sean T Duggan
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 3.  Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Authors:  Larosa Maddalena; Francesca Trentin; Mariele Gatto; Margherita Zen; Linda Nalotto; Francesca Saccon; Elisabetta Zanatta; Luca Iaccarino; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

4.  Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus.

Authors:  Ioannis Parodis; Emil Åkerström; Christopher Sjöwall; Azita Sohrabian; Andreas Jönsen; Alvaro Gomez; Martina Frodlund; Agneta Zickert; Anders A Bengtsson; Johan Rönnelid; Iva Gunnarsson
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

Review 5.  Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

Authors:  Carlos Rodríguez Escalera; Ángela María Zurita Guisado; Francisco Javier Mateo; Noemí Bahamontes-Rosa; María Jesús García Villanueva
Journal:  Clin Rheumatol       Date:  2022-07-23       Impact factor: 3.650

6.  Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain.

Authors:  Maria Cevey; Jaime Calvo-Alén; Carlos Crespo; Angel Robles-Marhuenda; Lee Smolen; Josefina Cortés-Hernández
Journal:  Clinicoecon Outcomes Res       Date:  2019-12-05

7.  Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.

Authors:  A Babini; A M Cappuccio; C Caprarulo; G Casado; A Eimon; H Figueredo; M A García; S Magri; P Mannucci; S Perez Rodriguez; B A Pons-Estel; E J Velozo; M Iglesias-Rodriguez; G Streger
Journal:  Lupus       Date:  2020-08-14       Impact factor: 2.911

Review 8.  10 Years of belimumab experience: What have we learnt?

Authors:  Roger A Levy; Tania Gonzalez-Rivera; Munther Khamashta; Norma Lynn Fox; Angela Jones-Leone; Bernie Rubin; Susan W Burriss; Kerry Gairy; Andre van Maurik; David A Roth
Journal:  Lupus       Date:  2021-07-08       Impact factor: 2.911
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.